NCT02250157View on ClinicalTrials.gov

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 5, 2014

Primary Completion Date

March 4, 2020

Study Completion Date

March 4, 2020

Conditions
Solid Tumor
Interventions
DRUG

Oratecan

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

80045

University of Colorado Cancer Center, Aurora

Sponsors

Lead Sponsor

Athenex, Inc.
All Listed Sponsors
lead

Athenex, Inc.

INDUSTRY